Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Weighted Average) (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $76.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 5.33% year-over-year to $76.5 million; the trailing twelve-month figure through Mar 2026 stood at $76.5 million (up 5.33% YoY), and the FY2025 full-year result was $74.2 million, up 3.89% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $76.5 million, up from $74.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $76.5 million in Q1 2026, with the low at $69.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $71.3 million across 5 years, with a median of $70.6 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) gained 0.89% — and 2026, when it rose 5.33%.
• Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) stood at $69.4 million in 2022, then grew by 0.98% to $70.1 million in 2023, then gained by 1.95% to $71.4 million in 2024, then advanced by 3.89% to $74.2 million in 2025, then advanced by 3.12% to $76.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $76.5 million (Q1 2026), $74.2 million (Q4 2025), and $73.6 million (Q3 2025), per Business Quant data.